Interestingly, this compound showed stronger therapeutic potential than more balanced compounds in a preclinical model of glaucoma, suggesting that dissociating β-arrestin1 from β-arrestin2 recruitment could be beneficial when targeting CB1 in this context. This evidence concerns the gene CNR1 and glaucoma.